Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
Chesney, Jason A., Ribas, Antoni, Long, Georgina V.
, Kirkwood, John M.
, Dummer, Reinhard, Puzanov, Igor
, Hoeller, Christoph, Gajewski, Thomas F., Gutzmer, Ralf, Rutkowski, Piotr
, Demidov, Lev, Arenberger, Petr, Shin, Sang Joon, Ferrucci, Pier Francesco, Haydon, Andrew, Hyngstrom, John, van Thienen, Johannes V., Haferkamp, Sebastian
, Guilera, Josep Malvehy, Rapoport, Bernardo Leon
, VanderWalde, Ari, Diede, Scott J.
, Anderson, James R., Treichel, Sheryl, Chan, Edward L., Bhatta, Sumita, Gansert, Jennifer, Hodi, Frank Stephen and Gogas, Helen
(2023)
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
Journal of Clinical Oncology 41 (3), pp. 528-540.
Date of publication of this fulltext: 18 Mar 2025 10:11
Article
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Journal of Clinical Oncology | ||||
| Publisher: | LIPPINCOTT WILLIAMS & WILKINS | ||||
|---|---|---|---|---|---|
| Place of Publication: | PHILADELPHIA | ||||
| Volume: | 41 | ||||
| Number of Issue or Book Chapter: | 3 | ||||
| Page Range: | pp. 528-540 | ||||
| Date | 2023 | ||||
| Institutions | Medicine > Lehrstuhl für Dermatologie und Venerologie | ||||
| Identification Number |
| ||||
| Keywords | COMBINED NIVOLUMAB; IPILIMUMAB; MONOTHERAPY; SURVIVAL; CRITERIA | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 76248 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric